Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any hypertrophic cardiomyopathy in which the cause of the disease is a mutation in the VCL gene.
Features include always present findings: Myofiber disarray, Cardiomyocyte hypertrophy, Hyperdynamic left ventricular ejection fraction, and Apical hypertrophic cardiomyopathy and others.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Heart and blood vessels | 7 | Hyperdynamic left ventricular ejection fraction, Apical hypertrophic cardiomyopathy, High blood pressure in lung arteries (pulmonary arterial hypertension) |
VCL function has not been fully characterized.
Hypertrophic cardiomyopathy 15 is associated with mutations in the VCL gene on chromosome 10.
Genetic testing for VCL is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for hypertrophic cardiomyopathy 15 has been reported in the published literature.
Phenotype severity distribution: 10 always present features.
No clinical trials have been registered for hypertrophic cardiomyopathy 15.
253 publications have been identified in PubMed for hypertrophic cardiomyopathy 15. Research spans Epidemiology / Natural History (22%), Clinical Trial Publication (22%), and Basic Science / Preclinical (19%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 56 | 22% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 6:45 AM UTC
Online Mendelian Inheritance in Man
Lungs and breathing | 2 | High blood pressure in lung arteries (pulmonary arterial hypertension), Exertional dyspnea |
Clinical study results
55 |
22% |
Laboratory research | 47 | 19% |
Research summaries | 44 | 17% |
Testing and diagnosis research | 40 | 16% |
Other research | 4 | 2% |
Patient case studies | 4 | 2% |
New treatment approaches | 3 | 1% |
So ACF (2026). [PMID: 41577587](https://pubmed.ncbi.nlm.nih.gov/41577587/). *Heart Lung Circ*. [Epidemiology / Natural History]
Weberling LD (2026). [PMID: 41707948](https://pubmed.ncbi.nlm.nih.gov/41707948/). *J Cardiovasc Magn Reson*. [Clinical Trial Publication]
Santner V (2026). [PMID: 41984359](https://pubmed.ncbi.nlm.nih.gov/41984359/). *Heart Fail Rev*. [Epidemiology / Natural History]
Aimo A (2026). [PMID: 41591616](https://pubmed.ncbi.nlm.nih.gov/41591616/). *Int J Cardiovasc Imaging*. [Epidemiology / Natural History]
Jain SS (2026). [PMID: 41213043](https://pubmed.ncbi.nlm.nih.gov/41213043/). *JAMA Cardiol*. [Clinical Trial Publication]
Qian J (2026). [PMID: 41720603](https://pubmed.ncbi.nlm.nih.gov/41720603/). *Open Heart*. [Other]
Bos JM (2026). [PMID: 41676920](https://pubmed.ncbi.nlm.nih.gov/41676920/). *J Am Heart Assoc*. [Other]
Dinshaw L (2026). [PMID: 41614294](https://pubmed.ncbi.nlm.nih.gov/41614294/). *J Am Heart Assoc*. [Epidemiology / Natural History]
Massera D (2026). [PMID: 41404743](https://pubmed.ncbi.nlm.nih.gov/41404743/). *J Am Heart Assoc*. [Other]
Liu N (2026). [PMID: 40884535](https://pubmed.ncbi.nlm.nih.gov/40884535/). *J Magn Reson Imaging*. [Epidemiology / Natural History]